datopotamab deruxtecan-dlnk (Datroway)
datopotamab deruxtecan-dlnk is an FDA-licensed reference biologic from Daiichi Sankyo, Inc. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Datroway datopotamab deruxtecan-dlnk
Daiichi Sankyo, Inc
- Approved
- Jan 17, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for datopotamab deruxtecan-dlnk, in chronological order.
Reference approval
Approval date of the reference datopotamab deruxtecan-dlnk product.
1 yr 5 mo ago
Frequently asked questions
Are there biosimilars approved for datopotamab deruxtecan-dlnk (Datroway)?
No 351(k) biosimilars or interchangeable biosimilars referencing datopotamab deruxtecan-dlnk are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.